- Conditions
- COVID-19
- Interventions
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg, Placebo, mRNA-CR-04 vaccine 3μg
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myocarditis
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more
- Conditions
- SARS-CoV-2, Influenza, RSV
- Interventions
- mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
- Conditions
- COVID-19, Long Haul
- Interventions
- Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
- Drug · Diagnostic Test · Biological + 3 more
- Lead sponsor
- Well- Konnect Healthcare Services and Research Firm
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SARS-CoV-2 Infection
- Interventions
- PRIME-2-CoV_Beta
- Drug
- Lead sponsor
- Speransa Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Florida City, Florida • Chicago, Illinois • Kansas City, Missouri + 2 more
- Conditions
- COVID-19
- Interventions
- COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline)
- Drug
- Lead sponsor
- Invivyd, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Systemic Allergic Reaction
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30,415 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273.214, mRNA-1273.815
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 1,807 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 48
- States / cities
- Bessemer, Alabama • Banning, California • Montebello, California + 38 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2, BNT162b2.B.1.351
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 1,574 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 17
- States / cities
- Oakland, California • Milford, Connecticut • Hialeah, Florida + 13 more
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Interventions
- mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
- Interventions
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Biological · Other
- Lead sponsor
- GeoVax, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more
- Conditions
- Kidney Transplant Recipients, Liver Transplant Recipients
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- COVID-19 Vaccines
- Interventions
- BNT162b2
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Homestead, Florida • Miami Lakes, Florida • Atlanta, Georgia + 10 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 16,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 139
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more
- Conditions
- Influenza, SARS-CoV-2
- Interventions
- mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
- Conditions
- Healthy, Chronic Stable Illness
- Interventions
- casirivimab+imdevimab, Moderna mRNA-1273 vaccine
- Drug · Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Hialeah, Florida + 3 more
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
- Interventions
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG, Antibiotics, Anti-viral agents, Anti-fungal agent, Anti-emetics
- Biological · Diagnostic Test · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273, Placebo, mRNA-1273.351
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Savannah, Georgia • Newton, Kansas • Kansas City, Missouri + 5 more
- Conditions
- Papillomavirus Infections, Coronavirus Disease (COVID-19)
- Interventions
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
- Conditions
- COVID-19
- Interventions
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
- Conditions
- COVID-19
- Interventions
- Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
- Conditions
- COVID-19
- Interventions
- Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pasadena, California